Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

First-line therapy for CML: nilotinib comes of age.

Davies J.

Lancet Oncol. 2011 Sep;12(9):826-7. doi: 10.1016/S1470-2045(11)70228-5. Epub 2011 Aug 17. No abstract available.

PMID:
21856227
2.

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.

Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP.

Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17. Erratum in: Lancet Oncol. 2011 Oct;12(11):989.

PMID:
21856226
3.

10 years of progress in chronic myelogenous leukemia.

Jabbour E, Mathisen MS, O'Brien S.

J Natl Compr Canc Netw. 2012 Sep;10(9):1049-53. No abstract available.

PMID:
22956803
4.

Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene.

Okada M, Satake A, Kaida K, Taniguchi K, Yoshihara S, Ikegame K, Tamaki H, Soma T, Fujimori Y, Ogawa H.

Int J Hematol. 2011 Feb;93(2):243-6. doi: 10.1007/s12185-011-0769-z. Epub 2011 Feb 1.

PMID:
21279819
5.

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.

Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, Vigneri P, Nicotera P, Dyer MJ, Holyoake T, Salomoni P, Calabretta B.

J Clin Invest. 2009 May;119(5):1109-23. doi: 10.1172/JCI35660. Epub 2009 Apr 13. Erratum in: J Clin Invest. 2013 Aug 1;123(8):3634.

7.

Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy.

Press RD.

Oncologist. 2010;15(7):744-9. doi: 10.1634/theoncologist.2010-0055. Epub 2010 Jun 21. No abstract available.

8.

Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?

Jabbour E, Kantarjian H, Cortes J.

Semin Hematol. 2010 Oct;47(4):344-53. doi: 10.1053/j.seminhematol.2010.06.002. Review.

PMID:
20875551
9.

As leukemia options grow, drugs jockey to be first-line therapies.

Dolgin E.

Nat Med. 2013 Jan;19(1):7. doi: 10.1038/nm0113-7. No abstract available.

PMID:
23295994
10.

Important therapeutic targets in chronic myelogenous leukemia.

Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.

Clin Cancer Res. 2007 Feb 15;13(4):1089-97. Review.

11.

The expanding role of nilotinib in chronic myeloid leukemia.

Kim TD, le Coutre P.

Expert Opin Drug Saf. 2011 Jan;10(1):97-107. doi: 10.1517/14740338.2011.532486. Epub 2010 Dec 2. Review.

PMID:
21121868
12.

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Goldman JM, Melo JV.

N Engl J Med. 2001 Apr 5;344(14):1084-6. No abstract available.

PMID:
11287980
13.

The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.

Maekawa T, Ashihara E, Kimura S.

Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22. Review.

PMID:
17929114
14.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P.

Blood. 2007 Nov 15;110(10):3540-6. Epub 2007 Aug 22.

15.

BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.

Wongboonma W, Thongnoppakhun W, Auewarakul CU.

Exp Mol Pathol. 2012 Apr;92(2):259-65. doi: 10.1016/j.yexmp.2012.01.007. Epub 2012 Jan 31.

PMID:
22314255
16.

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.

Hazarika M, Jiang X, Liu Q, Lee SL, Ramchandani R, Garnett C, Orr MS, Sridhara R, Booth B, Leighton JK, Timmer W, Harapanhalli R, Dagher R, Justice R, Pazdur R.

Clin Cancer Res. 2008 Sep 1;14(17):5325-31. doi: 10.1158/1078-0432.CCR-08-0308.

17.

Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.

Radich JP.

Cancer. 2012 Jan 15;118(2):300-11. doi: 10.1002/cncr.26280. Epub 2011 Jun 29. Review.

18.

Applying the discovery of the Philadelphia chromosome.

Sherbenou DW, Druker BJ.

J Clin Invest. 2007 Aug;117(8):2067-74. Review.

19.

Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.

Potenza L, Volzone F, Riva G, Soverini S, Martinelli S, Iacobucci I, Gnani A, Barozzi P, Forghieri F, Morselli M, Zanetti E, Maccaferri M, Baccarani M, Martinelli G, Torelli G, Luppi M.

Br J Haematol. 2009 Jul;146(2):227-30. doi: 10.1111/j.1365-2141.2009.07747.x. Epub 2009 May 26. No abstract available.

PMID:
19545285
20.

Chronic myelogenous leukemia. Preface.

DeAngelo DJ.

Hematol Oncol Clin North Am. 2011 Oct;25(5):ix-x. doi: 10.1016/j.hoc.2011.10.001. No abstract available.

PMID:
22054737
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk